Sanofi clinches second bellwether win in chemotherapy hair loss litigation – FiercePharma

Defending in the direction of Greater than 12,000 private damage lawsuits, Sanofi simply clinched a second win in ongoing litigation surrounding its chemcompletely differentapy drug Taxotere. 

The drugmaker enoughly warned plaintiff Elizabeth Kahn that the most cancers med might set off alopecia, or everlasting hair loss, a jury in A mannequin new Orleans federal courtroom found late final week. The selection marks Sanofi’s second bellwether win Inside the mass tort litigation, Reut…….

npressfetimg-3702.png

Defending in the direction of Greater than 12,000 private damage lawsuits, Sanofi simply clinched a second win in ongoing litigation surrounding its chemcompletely differentapy drug Taxotere. 

The drugmaker enoughly warned plaintiff Elizabeth Kahn that the most cancers med might set off alopecia, or everlasting hair loss, a jury in A mannequin new Orleans federal courtroom found late final week. The selection marks Sanofi’s second bellwether win Inside the mass tort litigation, Reuters reviews. 

Sanofi is “joyful” with the jury’s choice, An group spokesperson said over e-mail. “Taxotere stays An important chemcompletely differentapy selection, and we respect the jury’s willpower that the warnings included in our label for Taxotere have been enough,” she added.

Plaintiffs’ lawyer Chris Coffin of Pendley, Baudin & Coffin informed Reuters he was dissatisfied Inside The Outcome, however he stays “assured that the proof in the direction of Sanofi will Finish in constructive verdicts for plaintiffs Throughout the nation Finally.”

Associated: Johnson & Johnson scores 60-day maintain in extreme-profile talc litigation: report

Kahn plans to attrmovement the choice, Coffin added. 

Kahn sued Sanofi again in 2016. She claims she suffered everlasting hair loss after receiving Taxotere for breast most cancers starting in 2008. Sanofi knew the drug might Result in everlasting hair loss, pretty than the short-term hair loss extra generally Related to chemcompletely differentapy medicine, she alleges. She argued that Sanofi Did not evaluation The hazard of everlasting hair loss or warn doctors sufficiently. 

Had Kahn been Aware of the potential facet influence, she would have talked to her doctor about completely different medicine choices, Reuters says. 

Associated: Sanofi, GSK, Pfizer and Boehringer should face Zantac class-movement lawsuits, courtroom guidelines

U.S. District Decide Jane Triche Milazzo of the Japanese District of Louisiana is overseeing the case and hundreds of completely differents. The lawsuits have been launched in the direction of Sanofi and completely different drugmakers that produced and distrihowevered Taxotere or its generic mannequin, docetaxel.

Elsethe place, Sanofi faces lawsuits in New Jersey, California and Delconscious, plus Mississippi, the place the lawyer widespread has sued The agency over its advertising of the drug. 

Sanofi snagged its first bellwether win in September 2019. On the time, a jury found that Sanofi’s drug hadn’t set offed the everlasting hair Lack of ancompletely different plaintiff, Barbara Earnest, Reuters reported at the time. 

Elsethe place on the authorized entrance, Sanofi has been having fun with protection for its as quickly as-properly-respectd drug Zantac. A judge in Florida final month scrapped requests from Sanofi, GlaxoSmithKline, Pfizer and Boehringer Ingelheim to throw out lawsuits from former Zantac sufferers asking for medical monitoring and compensation For his or her monetary losses. Personal damage lawsuits tied to the drug can proceed as properly, …….

Source: https://www.fiercepharma.com/pharma/sanofi-clinches-second-bellwether-win-chemotherapy-hair-loss-litigation

Leave a Reply

Your email address will not be published. Required fields are marked *